Jackson Creek Investment Advisors LLC Purchases New Stake in CareDx, Inc. $CDNA

Jackson Creek Investment Advisors LLC purchased a new stake in CareDx, Inc. (NASDAQ:CDNA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 26,990 shares of the company’s stock, valued at approximately $508,000.

Several other hedge funds have also recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its holdings in CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after buying an additional 1,280 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in CareDx by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock valued at $365,000 after buying an additional 1,675 shares during the period. FNY Investment Advisers LLC purchased a new position in CareDx in the third quarter valued at approximately $31,000. CWM LLC raised its holdings in CareDx by 119.1% in the fourth quarter. CWM LLC now owns 7,407 shares of the company’s stock valued at $140,000 after buying an additional 4,026 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after buying an additional 4,160 shares during the period.

Insider Activity

In other news, CEO John Walter Hanna, Jr. sold 10,282 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total transaction of $217,155.84. Following the completion of the sale, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is owned by corporate insiders.

CareDx Stock Up 2.9%

CDNA opened at $22.16 on Thursday. The firm has a market capitalization of $1.14 billion, a P/E ratio of -138.50 and a beta of 2.49. The firm’s 50 day moving average is $19.54 and its 200-day moving average is $19.07. CareDx, Inc. has a 52-week low of $10.96 and a 52-week high of $23.24.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.23. The company had revenue of $117.70 million for the quarter, compared to analyst estimates of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The business’s quarterly revenue was up 39.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 earnings per share. Equities analysts expect that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on CDNA. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Weiss Ratings lowered shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, February 27th. Wells Fargo & Company lifted their price objective on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Finally, BTIG Research lifted their price objective on shares of CareDx from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.00.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.